Skip to content

This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional, please visit our dedicated site for more information at beonemedicines.co.uk

BRUKINSA logo
Old couple smiling waling hand in hand

BRUKINSA is the only BTK inhibitor recommended by NICE and accepted by SMC in CLL, WM, R/R MZL and R/R MCL*3–18

chevron Take a closer look at the 6–year data in 1L CLL from SEQUOIA19 6 Year Icon
chevron Take a closer look at the 6–year data in 1L CLL from SEQUOIA19 6 Year Icon
chevron Take a closer look at the 6–year data in 1L CLL from SEQUOIA19 6 Year Icon

DESIGNED TO BE DIFFERENT

by minimising off-target effects in the treatment of B-cell malignancies20-23
Graph icon

Proven efficacy regardless of line of therapy, genetic status and patient populations19,24-27

Graph icon

A consistent safety profile demonstrated across B-cell malignancies for over five years1,19,27-29

Graph icon

Unmatched BTK inhibitor dosing flexibility1,30,31

Select an indication to learn more about BRUKINSA: